{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:49:37Z","timestamp":1791920977334,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T00:00:00Z","timestamp":1473724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1208\/s12249-016-0625-9","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T14:27:48Z","timestamp":1473776868000},"page":"1585-1594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of Abbreviated Impactor Measurements (AIM) and Efficient Data Analysis (EDA) for Dry Powder Inhalers (DPIs) Against the Full-Resolution Next Generation Impactor (NGI)"],"prefix":"10.1208","volume":"18","author":[{"given":"Megha","family":"Mohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sau","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changning","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Prasad","family":"Peri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Doub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,13]]},"reference":[{"key":"625_CR1","unstructured":"US Pharmacopeial Convention. United States Pharmacopeia; USP 37-NF 32_S1; Chapter 601-physical tests and determinations: inhalation and nasal drug products: aerosols, sprays, and powders-performance quality tests. US Pharmacopeial Convention,, Rockville, MD, USA; 2014."},{"issue":"3","key":"625_CR2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/089426803769017668","volume":"16","author":"VA Marple","year":"2003","unstructured":"Marple VA, Olson BA, Santhanakrishnan K, Mitchell JP, Murray SC, Hudson-Curtis BL. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part II: archival calibration. J Aerosol Med. 2003;16(3):301\u201324.","journal-title":"J Aerosol Med"},{"issue":"7","key":"625_CR3","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/jps.20091","volume":"93","author":"A Kamiya","year":"2004","unstructured":"Kamiya A, Sakagami M, Hindle M, Byron PR. Aerodynamic sizing of metered dose inhalers: an evaluation of the Andersen and next generation pharmaceutical impactors and their USP methods. J Pharm Sci. 2004;93(7):1828\u201337.","journal-title":"J Pharm Sci"},{"key":"625_CR4","unstructured":"Mitchell J, Mackay H, Avvakoumova V, Ali R, Nagel MW, editors. The abbreviated impactor measurement (AIM) concept: influence of particle bounce and re-entrainment\u2014application to the Copley fast screening Andersen impactor (C-FSA). Drug Delivery to the Lungs; 2008; Edinburgh, UK."},{"issue":"4","key":"625_CR5","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1208\/s12249-009-9312-4","volume":"10","author":"TP Tougas","year":"2009","unstructured":"Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Oort MV, et al. Improved quality control metrics for cascade impaction measurements of Oral Inhaled Drug Products (OIPs). AAPS PharmSciTech. 2009;10(4):1276\u201385. doi:\n10.1208\/s12249-009-9312-4\n\n.","journal-title":"AAPS PharmSciTech"},{"key":"625_CR6","unstructured":"Mitchell JP, editor. The abbreviated impactor measurement (AIM) concept for aerodynamic particle size distribution (APSD) in a quality-by-design (QbD) environment. Proc Biennial IPAC-RS Conference, Bethesda, MD, USA; 2008."},{"issue":"1","key":"625_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1208\/s12249-009-9202-9","volume":"10","author":"J Mitchell","year":"2009","unstructured":"Mitchell J, Nagel M, Avvakoumova V, MacKay H, Ali R. The abbreviated impactor measurement (AIM) concept: part 1\u2014influence of particle bounce and re-entrainment\u2014evaluation with a \u201cdry\u201d pressurized metered dose inhaler (pMDI)-based formulation. AAPS PharmSciTech. 2009;10(1):243\u201351. doi:\n10.1208\/s12249-009-9202-9\n\n.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"625_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1208\/s12249-009-9202-9","volume":"10","author":"J Mitchell","year":"2009","unstructured":"Mitchell J, Nagel M, Avvakoumova V, MacKay H, Ali R. The abbreviated impactor measurement (AIM) concept: part II\u2014influence of evaporation of a volatile component\u2014evaluation with a \u201cdroplet-producing\u201d pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent. AAPS PharmSciTech. 2009;10(1):252\u20137. doi:\n10.1208\/s12249-009-9202-9\n\n.","journal-title":"AAPS PharmSciTech"},{"key":"625_CR9","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-010-9473-1","author":"JP Mitchell","year":"2010","unstructured":"Mitchell JP, Nagel MW, Doyle CC, Ali RS, Avvakoumova VI, Christopher JD, et al. Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated Andersen cascade impactors (ACIs): part 2\u2014investigation of bias in extra-fine mass fraction with AIM-HRT impactor. AAPS PharmSciTech. 2010. doi:\n10.1208\/s12249-010-9473-1\n\n.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"625_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1208\/s12249-010-9452-6","volume":"11","author":"JP Mitchell","year":"2010","unstructured":"Mitchell JP, Nagel MW, Doyle CC, Ali RS, Avvakoumova VI, Christopher JD, et al. Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated Andersen cascade impactors (ACIs): part 1. AAPS PharmSciTech. 2010;11(2):843\u201351. doi:\n10.1208\/s12249-010-9452-6\n\n.","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"625_CR11","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1208\/s12249-013-9984-7","volume":"14","author":"C Guo","year":"2013","unstructured":"Guo C, Ngo D, Ahadi S, Doub WH. Evaluation of an abbreviated impactor for fine particle fraction (FPF) determination of metered dose inhalers (MDI). AAPS PharmSciTech. 2013;14(3):1004\u201311. doi:\n10.1208\/s12249-013-9984-7\n\n.","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"625_CR12","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/jps.22824","volume":"101","author":"MJ Donovan","year":"2012","unstructured":"Donovan MJ, Kim SH, Raman V, Smyth HD. Dry powder inhaler device influence on carrier particle performance. J Pharm Sci. 2012;101(3):1097\u2013107.","journal-title":"J Pharm Sci"},{"key":"625_CR13","unstructured":"Boehringer Ingelheim. Highlights of prescribing information; SPIRIVA\u00ae HandiHaler\u00ae (tiotropium bromide inhalation powder); capsules for respiratory inhalation. Available at: \nhttp:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing+Information\/PIs\/Spiriva\/Spiriva.pdf\n\n. Accessed: 2015 Mar 24."},{"issue":"2","key":"625_CR14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/jam.1993.6.99","volume":"6","author":"AR Clark","year":"1993","unstructured":"Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers\u2014implications for in vitro testing. J Aerosol Med. 1993;6(2):99\u2013110.","journal-title":"J Aerosol Med"},{"key":"625_CR15","unstructured":"Merck & Co., Inc. Highlights of prescribing information; FORADIL AEROLIZER (formoterol fumarate inhalation powder). Available at: \nhttp:\/\/www.merck.com\/product\/usa\/pi_circulars\/f\/foradil\/foradil_pi.pdf\n\n. Accessed: 2015 Mar 27."},{"issue":"3","key":"625_CR16","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/jps.21501","volume":"98","author":"A Kamiya","year":"2009","unstructured":"Kamiya A, Sakagami M, Byron PR. Cascade impactor practice for a high dose dry powder inhaler at 90 L\/min: NGI versus modified 6-stage and 8-stage ACI. J Pharm Sci. 2009;98(3):1028\u201339. doi:\n10.1002\/jps.21501\n\n.","journal-title":"J Pharm Sci"},{"key":"625_CR17","unstructured":"Byron PR. Compendial dry powder testing: USP perspectives. Respiratory Drug Delivery IV. 1994:153\u201362."},{"issue":"6","key":"625_CR18","first-page":"6","volume":"4","author":"R Bauer","year":"2010","unstructured":"Bauer R, Christopher D, Church T, Dey M, Glaab V, Goodey A, et al. Abbreviated impactor measurement (AIM) and efficient data analysis (EDA) concepts: a partnership for the assurance of oral inhaled product (OIP) quality. Inhalation. 2010;4(6):6\u201310.","journal-title":"Inhalation"},{"key":"625_CR19","unstructured":"Mitchell JP, Tougas T, Christopher JD, Lyapustina S, Glaab V, editors. The abbreviated impactor measurement and efficient data analysis concepts: why use them and when. RDD; 2012."},{"key":"625_CR20","unstructured":"Sheng G, Zhang J, Simmons R, Watanabe W. Fast screening impactor (FSI) as a prescreening tool for MDI and nebulizers. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, editors. RDD IX: Davis Healthcare Interrnational Publishing 2011. p. 637\u201340."},{"issue":"138\u2013144","key":"625_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/jamp.2012.0975","volume":"26","author":"R Delvadia","year":"2012","unstructured":"Delvadia R, Hindle M, Longest PW, Byron PR. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults. J Aerosol Med Pulm Drug Deliv. 2012;26(138\u2013144):7. doi:\n10.1089\/jamp.2012.0975\n\n.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"5","key":"625_CR22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0731-7085(03)00425-4","volume":"33","author":"SO Akapo","year":"2003","unstructured":"Akapo SO, Asif M. Validation of a RP-HPLC method for the assay of formoterol and its related substances in formoterol fumarate dihydrate drug substance. J Pharm Biomed Anal. 2003;33(5):935\u201345.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"625_CR23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0378-5173(02)00359-9","volume":"246","author":"R Price","year":"2002","unstructured":"Price R, Young PM, Edge S, Staniforth JN. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. Int J Pharm. 2002;246(1):47\u201359.","journal-title":"Int J Pharm"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-016-0625-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-016-0625-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-016-0625-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T12:09:56Z","timestamp":1498651796000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-016-0625-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,13]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1208\/s12249-016-0625-9","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,13]]}}}